FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3206131605> ?p ?o ?g. }

• W3206131605 abstract "Abstract Background Management of patients with atrial fibrillation (AF) and malignancy is a clinical challenge given the paucity of evidence supporting the appropriate clinical management. Purpose To evaluate the outcomes of patients with active or prior malignancy in a large contemporary cohort of European AF patients. Methods We analyzed patients enrolled in the ESC-EHRA EORP-AF General Long-Term Registry. We stratified the population into three categories (i) No Malignancy (NoM) (ii) Prior Malignancy (PriorM) and (iii) Active Malignancy (ActM). The primary outcome for this analysis was all-cause death among the three groups. The association between anticoagulant treatment, all-cause death and haemorrhagic events was also evaluated. Results Among the original 11 096 AF patients enrolled, 10 383 were included in this analysis (median age 71 years (interquartile range [IQR] 63–77, males 59.7%). Of these, 9 597 (92.4%) were NoM patients, 577 (5.6%) PriorM and 209 (2%) ActM. Patients with malignancy (prior or active) had a higher median age, median CHA2DS2-VASc and HAS-BLED scores, compared to patients without malignancy (p&lt;0.001). Lack of anticoagulation (AC) prescription occurred more commonly in ActM (21.5%) as compared with the other groups (PriorM 10.1% vs NoM 12.8%, p&lt;0.001). In case of AC treatment, patients with ActM were treated more frequently with heparins (ActM 8.1% vs PriorM 2.4% vs NoM 2%, p&lt;0.001). After a median follow-up of 730 days [IQR 692–749], 982 (9.5%) patients died. Among all deaths, the proportion of cardiovascular death was different according to the three groups (40.0% in NoM, 26.0% in PrioM and 22.2% in ActM, p=0.002). For all cause-death, Kaplan-Meier analysis showed a progressively higher cumulative risk in the PriorM and ActM groups compared to NoM patients (Figure 1). On multivariable Cox regression analysis, adjusted for CHA2DS2-VASc score, use of AC, type of AF and chronic kidney disease, ActM group was independently associated with a higher risk for all cause death (hazard ratio [HR] 2.90, 95% confidence interval [CI] 2.23–3.76) while PriorM group was not. Among PriorM and NoM patients, multivariable adjusted Cox regression analysis found that the use of any AC was independently associated with a lower risk for all-cause death (HR 0.36, 95% CI 0.19–0.66; HR 0.66, 95% CI 0.54–0.81). No significant association between AC and all-cause death was found for ActM patients. Conclusions In a large contemporary cohort of European AF patients, active malignancy was found to be independently associated with all-cause death. Use of any AC was associated with a lower risk for all-cause death in patients with no malignancies and with prior malignancies, but with no significant association amongst patients with active malignancies. FUNDunding Acknowledgement Type of funding sources: Other. Main funding source(s): Since the start of EORP, the following companies have supported the programme: Abbott Vascular Int. (2011–2021), Amgen Cardiovascular (2009–2018), AstraZeneca (2014–2021), Bayer (2009–2018), Boehringer Ingelheim (2009–2019), Boston Scientific (2009–2012), The Bristol Myers Squibb and Pfizer Alliance (2011–2016), The Alliance Daiichi Sankyo Europe GmbH and Eli Lilly and Company (2011–2017), Edwards (2016–2019), Gedeon Richter Plc. (2014–2017), Menarini Int. Op. (2009–2012), MSD-Merck & Co. (2011–2014), Novartis Pharma AG (2014–2020), ResMed (2014–2016), Sanofi (2009–2011), SERVIER (2010–2021), and Vifor (2019–2022). Figure 1. Kaplan-Meier for all-cause death" @default.
• W3206131605 created "2021-10-25" @default.
• W3206131605 creator A5007259309 @default.
• W3206131605 creator A5012570915 @default.
• W3206131605 creator A5034098541 @default.
• W3206131605 creator A5035512968 @default.
• W3206131605 creator A5042766039 @default.
• W3206131605 creator A5043025433 @default.
• W3206131605 creator A5044926484 @default.
• W3206131605 creator A5047995526 @default.
• W3206131605 creator A5048738698 @default.
• W3206131605 creator A5068566870 @default.
• W3206131605 creator A5084628427 @default.
• W3206131605 creator A5088321932 @default.
• W3206131605 date "2021-10-01" @default.
• W3206131605 modified "2023-10-16" @default.
• W3206131605 title "Impact of malignancy on outcomes in European patients with atrial fibrillation: a report from the ESC-EHRA EURObservational Research Programme in Atrial Fibrillation General Long-Term Registry" @default.
• W3206131605 doi "https://doi.org/10.1093/eurheartj/ehab724.2862" @default.
• W3206131605 hasPublicationYear "2021" @default.
• W3206131605 type Work @default.
• W3206131605 sameAs 3206131605 @default.
• W3206131605 citedByCount "0" @default.
• W3206131605 crossrefType "journal-article" @default.
• W3206131605 hasAuthorship W3206131605A5007259309 @default.
• W3206131605 hasAuthorship W3206131605A5012570915 @default.
• W3206131605 hasAuthorship W3206131605A5034098541 @default.
• W3206131605 hasAuthorship W3206131605A5035512968 @default.
• W3206131605 hasAuthorship W3206131605A5042766039 @default.
• W3206131605 hasAuthorship W3206131605A5043025433 @default.
• W3206131605 hasAuthorship W3206131605A5044926484 @default.
• W3206131605 hasAuthorship W3206131605A5047995526 @default.
• W3206131605 hasAuthorship W3206131605A5048738698 @default.
• W3206131605 hasAuthorship W3206131605A5068566870 @default.
• W3206131605 hasAuthorship W3206131605A5084628427 @default.
• W3206131605 hasAuthorship W3206131605A5088321932 @default.
• W3206131605 hasBestOaLocation W32061316051 @default.
• W3206131605 hasConcept C119060515 @default.
• W3206131605 hasConcept C126322002 @default.
• W3206131605 hasConcept C141071460 @default.
• W3206131605 hasConcept C187212893 @default.
• W3206131605 hasConcept C201903717 @default.
• W3206131605 hasConcept C2779159551 @default.
• W3206131605 hasConcept C2779161974 @default.
• W3206131605 hasConcept C2779399171 @default.
• W3206131605 hasConcept C71924100 @default.
• W3206131605 hasConcept C72563966 @default.
• W3206131605 hasConceptScore W3206131605C119060515 @default.
• W3206131605 hasConceptScore W3206131605C126322002 @default.
• W3206131605 hasConceptScore W3206131605C141071460 @default.
• W3206131605 hasConceptScore W3206131605C187212893 @default.
• W3206131605 hasConceptScore W3206131605C201903717 @default.
• W3206131605 hasConceptScore W3206131605C2779159551 @default.
• W3206131605 hasConceptScore W3206131605C2779161974 @default.
• W3206131605 hasConceptScore W3206131605C2779399171 @default.
• W3206131605 hasConceptScore W3206131605C71924100 @default.
• W3206131605 hasConceptScore W3206131605C72563966 @default.
• W3206131605 hasIssue "Supplement_1" @default.
• W3206131605 hasLocation W32061316051 @default.
• W3206131605 hasOpenAccess W3206131605 @default.
• W3206131605 hasPrimaryLocation W32061316051 @default.
• W3206131605 hasRelatedWork W10296644 @default.
• W3206131605 hasRelatedWork W10367265 @default.
• W3206131605 hasRelatedWork W11633418 @default.
• W3206131605 hasRelatedWork W4844954 @default.
• W3206131605 hasRelatedWork W762865 @default.
• W3206131605 hasRelatedWork W769599 @default.
• W3206131605 hasRelatedWork W82946 @default.
• W3206131605 hasRelatedWork W9443099 @default.
• W3206131605 hasRelatedWork W9477167 @default.
• W3206131605 hasRelatedWork W7954022 @default.
• W3206131605 hasVolume "42" @default.
• W3206131605 isParatext "false" @default.
• W3206131605 isRetracted "false" @default.
• W3206131605 magId "3206131605" @default.
• W3206131605 workType "article" @default.